Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)

NCT02245737 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02245737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02245737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Lead sponsor
AstraZeneca
Phase
Phase 2/3
Overall status
Terminated
Start date
September 30, 2014
Completion date
October 4, 2018
Enrollment
2,218 (actual)
Sites
254

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer´s disease